Immunothrombosis in Acute Ischemic Stroke
- PMID: 39479751
- DOI: 10.1161/STROKEAHA.124.048137
Immunothrombosis in Acute Ischemic Stroke
Abstract
Ischemic stroke is one of the leading causes of disability and mortality worldwide. Thrombosis is the main pathological process of stroke and is therefore an important therapeutic target in stroke prevention. In recent years, with the development of endovascular treatment and therefore retrieving the thrombus for further investigation, evidence is accumulating that immune cells are inextricably linked to stroke pathogenesis. Circulating immune cells have been found to induce immunothrombosis, and they actively participate in the formation of the thrombus by promoting platelet recruitment and thrombin activation. Additionally, the formation of thromboinflammation leads to increased instability of atherosclerotic plaques. We review the concepts of stroke immunothrombosis and thromboinflammation and the effect of immune cells on vessel recanalization and patient outcome. In addition, we elaborate on the possible mechanism of immune cells being activated and participating in thrombosis in ischemic stroke.
Keywords: ischemic stroke; plaque, atherosclerotic; stroke; thromboinflammation; thrombosis.
Conflict of interest statement
Dr Coutinho reports fundings from Boehringer Ingelheim, Bayer, and AstraZeneca, and is a cofounder and shareholder of TrianecT. The other authors report no conflicts.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical